[CAS NO. 53774-63-3] L-NIL
PRODUCTS SPECIFICATIONS [53774-63-3]
DESCRIPTION [53774-63-3]
Overview
| MDL | MFCD20542775 |
|---|---|
| Molecular Weight | 187.24 |
| Molecular Formula | C8H17N3O2 |
| SMILES | N[C@@H](CCCCNC(C)=N)C(O)=O |
1 Publications Citing Use of MCE
Summary
L-NIL is an inducible NO synthase inhibitor, with an IC 50 of 3.3 μM for miNOS [1] [2] [3] .
IC50 & Target
IC50: 3.3 μM (mouse inducible NO synthase), 92 μM (rat brain constitutive NO synthase) [1]
In Vitro
L-NIL produces a concentration-dependent inhibition of both the mouse inducible NOS (miNOS) and the rat brain constitutive NOS (rcNOS) and is considerably more potent for miNOS. The IC 50 values for L-NIL with miNOS and rcNOS are 3.3 and 92 pM, respectively, indicating that L-NIL is 28-fold more selective for miNOS. In addition, L-NIL has approximately 6-fold greater potency for miNOS than either L-NMA or L-NNA [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
L-NIL (10 and 30 mg/kg, IP) prevents the inflammation, oxidative stress and autophagy induced by renal IR in mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Adult male Balb/c (20-25 g) [1] . |
| Dosage: | 10 and 30 mg/kg. |
| Administration: | Intraperitoneally at the end of CLP and at 6 h after sepsis induction. |
| Result: |
Led to a negligible increase in plasma NGAL compared to sham mice.
Led to a significant decrease in both TLR4 and IL1βprotein contents and clusterin transcript. Showed an increase in NFAT5 mRNA levels, as compared with mice treated with vehicle. Promoted a decrease in AR protein expression, as compared with animals treated with vehicle. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : 50 mg/mL ( 267.04 mM ; Need ultrasonic)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.3407 mL | 26.7037 mL | 53.4074 mL |
| 5 mM | 1.0681 mL | 5.3407 mL | 10.6815 mL |
| 10 mM | 0.5341 mL | 2.6704 mL | 5.3407 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (534.07 mM); Clear solution; Need ultrasonic
References
- [1] Consuelo Pasten, et al. l-NIL prevents the ischemia and reperfusion injury involving TLR-4, GST, clusterin, and NFAT-5 in mice. Am J Physiol Renal Physiol. 2019 Apr 1;316(4):F624-F634.
- [2] Sharon Angela Tanuseputero, et al. Intravenous Arginine Administration Downregulates NLRP3 Inflammasome Activity and Attenuates Acute Kidney Injury in Mice with Polymicrobial Sepsis. Mediators Inflamm. 2020 May 11;2020:3201635.
- [3] Moore WM, et al. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem. 1994 Nov 11;37(23):3886-8.
